Company / Free Cash Flow
NovaBay Pharmaceuticals, Inc. Free Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$5.2M
FY2024
5-year range
-$9.2M / -$4.3M
FY2020-FY2024
Trend
-21.2%
vs FY2023
Sector context
#66 of 192
Health Care
What the data says
At -$5M, NovaBay Pharmaceuticals, Inc.'s free cash flow ranks #66 of 192 in the Health Care sector. Free Cash Flow has fluctuated over the past 10 years, ranging from -$19M in FY2015 to -$4M in FY2023.
Based on SEC 10-K filings.
-$5M in FY2024.
Improved from -$7M to -$5M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#66 of 192 in Health CareTop 34% of 192This company -$5.2M Sector average $474.2M
▼
-101.1% below sector average
Key checks
Key Insights
- In FY2024, free cash flow decreased 21.2% year-over-year.
- Ranks #66 out of 192 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2023.
- Lowest free cash flow in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$5.2M | -21.2% |
| FY2023 | -$4.3M | +36.7% |
| FY2022 | -$6.8M | +26.8% |
| FY2021 | -$9.2M | -94.7% |
| FY2020 | -$4.7M | +40.3% |
| FY2019 | -$7.9M | -41.6% |
| FY2018 | -$5.6M | +13.8% |
| FY2017 | -$6.5M | +44.9% |
| FY2016 | -$11.8M | +36.7% |
| FY2015 | -$18.7M | -23.5% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026